Victoria University Research Repository (VURR)
metadata only
Is Europe a Laggard in Pharmaceuticals? R&D Joint Ventures, Patent Quality and R&D Productivity
Has the USA overtaken Europe as the powerhouse of new medicines? If so, is this attributable to a flight of business expenditure in R&D to the USA? This paper answers these questions using a methodology that focuses on R&D productivity and patent quality as key indicators of innovation, accounts f
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Pharmaceutical Public-Private Partnerships in the United States and Europe: Moving from the Bench to the Bedside#271038
- The impact of the pharmaceutical industry on the innovation performance of European countries#271035
- Implications of the Business Strategies of Pharmaceutical Companies for Industry Developments in Australia#1026056
- Exploring Regulatory Flexibility to Create Novel Incentives to Optimize Drug Discovery#87697
- The waves of Biotechnological Innovation in Medicine : Interfirm Cooperation Effects and a Venture Capital Perspective#271006
Record · ID 1026057
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive